EyePoint Shares Plunge 69% After DURAVYU Phase 3 Trial Misses Primary Endpoint
EyePoint, Inc. (EYPT) shares fell about 69% after topline results from the LUGANO Phase 3 trial of DURAVYU in wet age-related macular degeneration missed the primary endpoint. The stock traded around $4.585 on Monday versus a prior close of $14.75. An ad hoc analysis excluding a 4% cohort suggested non-inferiority to on-label aflibercept.
How this was made
The 30-second read
Why it matters
A Phase 3 primary endpoint miss typically raises the probability of additional trials, label setbacks, or slower commercialization timelines, which can reprice the equity quickly.
Market read
The headline risk is development failure at the primary endpoint level, with only limited consolation from an ad hoc non-inferiority analysis.
What to watch
The article does not state whether regulators will accept the ad hoc analysis, nor does it provide safety, effect size, or subgroup consistency, which are key for reassessing the program’s true risk.
Background
EyePoint reported topline results from the LUGANO Phase 3 trial of DURAVYU for wet age-related macular degeneration.
Ticker impact
EyePoint shares plunged after DURAVYU Phase 3 LUGANO topline results missed the primary endpoint, driving a sharp selloff.
Further volatility and downside bias likely, with relief only if follow-up analyses or secondary endpoints support non-inferiority claims.
The article reports a Phase 3 primary endpoint miss and quantifies the immediate trading reaction (about -69%), which typically dominates near-term risk/reward for biotech programs.
Market effects
Wet AMD and retina drug development sentiment may soften as another Phase 3 program fails its primary endpoint.
US Nasdaq biotech complex likely sees spillover selling on development-risk headlines.
Limited, unless the result changes broader expectations for competitive efficacy in wet AMD.
Counterpoint
The ad hoc analysis excluding a 4% asymmetric cohort suggests DURAVYU could be non-inferior, which may support a rebound if investors focus on the totality of evidence rather than the primary endpoint alone.
Key entities
- companyEyePoint, Inc.
Sponsor of the DURAVYU Phase 3 LUGANO trial; subject of the reported stock plunge.
- drugDURAVYU
EyePoint’s investigational therapy in wet AMD whose Phase 3 primary endpoint was missed.
- clinical_trialLUGANO Phase 3 trial
The Phase 3 study whose topline results drove the immediate market reaction.
